Revenue: As of FY2027 Q1, the actual value is USD 1.493 B, missing the estimate of USD 1.495 B.

EPS: As of FY2027 Q1, the actual value is USD 2.04, beating the estimate of USD 1.982.

EBIT: As of FY2027 Q1, the actual value is USD 298.5 M.

STERIS plc announced a targeted consolidation plan involving the centralization of manufacturing and distribution for formulated chemistries into a new Center of Excellence in North Carolina, which includes the expected closure of facilities in St. Louis, Missouri, and Plymouth, Minnesota. STERIS plc projects total pre-tax restructuring charges of approximately $55 million to $70 million, with completion expected during fiscal 2030. These charges are composed of $40 million to $50 million in cash expenditures and $15 million to $20 million in non-cash charges. These projected charges will be excluded from adjusted earnings measurements.